IHI project leads animal test to be dropped

9 September 2024

The Innovative Health Initiative (IHI) - a European Union (EU) public-private partnership funding health research and innovation - has boasted that it has made a major step forward for animal welfare.

This relates to the tests that must be run by manufacturers before a new batch of medicines can be released for use to check that it is safe for patients, whether human or animal.

The tests required to assess the safety and quality of different types of medicines are set out in a reference work called the European Pharmacopoeia. For medicines administered by injection, such as vaccines, some antibiotics, and blood products, manufacturers have to test for pyrogens, contaminants which can trigger a fever. 

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK



Today's issue

Company Spotlight





More Features in Pharmaceutical